104P - Stereotactic body radiation therapy in early-stage non-small cell lung cancer in elderly patients: Safety and efficacy

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Non-small-cell lung cancer
Geriatric Oncology
Surgical oncology
Therapy
Radiation oncology
Presenter Xiangpeng Zheng
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors X. Zheng1, Y. Ren2, W. Ge2
  • 1Radiation Oncology, Huadong Hospital, Fudan University, 200040 - Shanghai/CN
  • 2Radiation Oncology, Huadong Hospital affiliated to Fudan University, Shanghai/CN

Abstract

Background

Elderly patients with early-staged non-small cell lung cancer (NSCLC) have limited options for definitive treatment due to various co-morbidities. This study aims to assess the safety and efficacy of stereotactic body radiation therapy (SBRT) in this specific patient population.

Methods

Twenty patients of above 75 years old with early-staged NSCLC received SBRT with written contents in past four years. Clinical history, radiotherapy records, treatment outcomes, including tumor local control and toxicity profiles were retrospectively collected and analyzed. Regression analysis was applied to investigate the correlation between radiation pneumonitis (RP) and dosimetric parameters.

Results

All patients completed the planned radiotherapy without interruption or cancelation and no evident treatment-related symptom was seen during the radiotherapy course. The longest follow-up period was 19 months with a median of 11 months. The tumor local control was 95%. The gross incidence of RP was 55%, while symptomatic RP was 20%. Radiologically, the extent of RP was limited. Multiple-variable regression analysis showed there existed significant statistical correlation between RP and V20, V30.

Conclusions

SBRT is an option for elderly patients with localized NSCLC with satisfactory safety and efficacy, especially in tumor local control and maintenance of quality of life.

Clinical trial identification

N/A

Legal entity responsible for the study

Huadong Hospital, Fudan University

Funding

the National Natural Science Foundation of China (No. 81472794)

Disclosure

All authors have declared no conflicts of interest.